Interestingly, erlotinib is indicated in the global population and has demonstrated its efficacy in a non-mutated EGFR NSCLC population without an identified response or resistance-marker to date [308], highlighting EGFR-TKIs activity in non-mutant tumours, and the lack of relevant markers in this situation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.